Curasight A/S (NGM: CURAS)

Market Cap	285.75M
Revenue (ttm)	n/a
Net Income (ttm)	-48.98M
Shares Out	20.68M
EPS (ttm)	-2.40
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,272
Open	9.00
Previous Close	8.96
Day's Range	8.96 - 9.34
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 21, 2025

About Curasight

Curasight A/S, a biotech company, develops treatment of cancer. The company exploits a novel Positron Emissions Tomography (PET) imaging platform that targets the urokinase-type plasminogen activator receptor (uPAR). It develops uTRACE for enhanced evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trials; and uTREAT, a uPAR targeted radionuclide therapy is using uTRACE together with radiation therapy to irradiate cancer with limited irradiation of healthy tissue. The company focuses on gen...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2013
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: CURAS

Financial Performance

Financial numbers in DKK